NASDAQ Composite ended the session with Moderna jumping 4.85% to $130.08 on Thursday, following last session’s downward trend. NASDAQ Composite fell 0.04% to $13,123.94, after two successive sessions in a row of gains, on what was a somewhat rough trend trading session today.

Moderna today’s close was $130.08, 37.22% under its 52-week high of $178.50.

Moderna’s Sales

Moderna’s sales growth is 1986.4% for the current quarter and 19117.5% for the next. The company’s growth estimates for the current quarter and the next is 18.9% and 660%, respectively.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Volatility

Moderna’s last day, last week, and last month’s average volatility was a negative 0.39%, a positive 1.35%, and a negative 1.17%, respectively.

Moderna’s last day, last week, and last month’s high and low average amplitude percentage was 5.67%, 7.02%, and 8.45%, respectively.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $130.08 at 17:25 EST, way under its 52-week high of $178.50 and way higher than its 52-week low of $17.91.

Moderna’s Moving Average

Moderna’s value is below its 50-day moving average of $133.18 and way above its 200-day moving average of $86.91.

Previous days news about Moderna

According to Bloomberg Quint on Monday, 11 January, "The move, announced by Biden’s office Friday and supported by a group of Democratic governors, represents a gamble by the incoming administration that there will be enough vaccine available to ensure second shots after 21 days for the Pfizer-BioNTech vaccine, and 28 days for the Moderna shot."

According to Bloomberg Quint on Monday, 11 January, "The move, announced by Biden’s office Friday and supported by a group of Democratic governors, represents a gamble by the incoming administration that there will be enough supply available to ensure timely second shots for both the Pfizer-BioNTech and Moderna vaccines."

According to MarketWatch on Monday, 11 January, "The U.S. counted at least 208,338 cases on Sunday, and German partner BioNTech SE , and one developed by Moderna Inc. , with much fanfare in December."

According to Business Insider on Tuesday, 12 January, "With the Oxford and Pfizer vaccines currently being rolled out and the Moderna vaccine becoming the third COVID jab approved in the UK, employers are now one step closer to getting their businesses back up and running again. "

According to Business Insider on Tuesday, 12 January, "The exception is the Moderna vaccine, which can be stored at higher temperature than some of the others, like Pfizer-BioNtech, Maxson said."

According to Bloomberg Quint on Wednesday, 13 January, "It’s also immunizing people with products from Moderna Inc. as well as a collaboration between Pfizer Inc. and BioNTech SE."

LEAVE A REPLY

Please enter your comment!
Please enter your name here